Health Care·Pharmaceuticals·$11.4B
Elanco Animal Health (ELAN) is a global leader in animal health products, focusing on pharmaceuticals and vaccines for livestock and pets. As a key player in the health care sector, Elanco addresses growing concerns about animal health and food safety, which are increasingly important in today's world.
Earnings Per Share (EPS)
EPS is a critical indicator of the company's profitability and financial health, reflecting how much profit is allocated to each share of stock.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products, which is essential for assessing growth.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
4Q
EPS Beat Rate
88%
Avg EPS Surprise
+21.77%
Avg Stock Reaction
+10.74%
In Q4-2025, Elanco reported an EPS of $0.13, exceeding expectations by 16.07%. The stock responded positively, gaining 6.59% the following day.
Management Promises & Guidance
Analysts expect Elanco to report a solid performance in Q1-2026, with a consensus EPS of $0.34 and revenue of $1.3 billion. The market is closely watching for any signs of growth or challenges in the animal health sector.
Bull Case
If Elanco beats EPS estimates and shows strong revenue growth, it could indicate robust demand for its products, leading to increased investor confidence and a potential stock rally.
Bear Case
Conversely, if the company misses estimates or provides weak guidance, it could raise concerns about market conditions and competitive pressures, resulting in a decline in stock price.
Earnings Per Share (EPS)
$0.34EPS is a critical indicator of the company's profitability and financial health, reflecting how much profit is allocated to each share of stock.
Revenue
$1.3BRevenue figures provide insight into the company's sales performance and market demand for its products, which is essential for assessing growth.
The print will turn on these two things.
Q1
Will Elanco's EPS exceed the consensus estimate of $0.34?
A beat on EPS could signal strong operational performance and boost investor confidence, while a miss could raise concerns about profitability.
Q2
What revenue growth can Elanco report compared to the consensus of $1.3 billion?
Revenue growth is crucial for assessing market demand and the effectiveness of Elanco's product offerings, impacting future guidance.
Why consensus could be wrong
The Street may be underestimating Elanco's ability to capitalize on emerging trends in animal health, particularly in the pet care segment, which has been growing rapidly.
Supporting Evidence
Recent product launches have shown strong initial demand, suggesting potential upside to revenue forecasts.
Elanco's focus on innovation could lead to better-than-expected sales in key markets.
The company's historical performance indicates a high likelihood of beating EPS estimates.
Key Risk
If Elanco can demonstrate significant growth in its pet care products, it could challenge the current revenue estimates.
Pre-commit to what would confirm each case.
This quarter, the market is debating whether Elanco can maintain its growth momentum amid competitive pressures and changing market dynamics.
Bull Confirmed If
An EPS of $0.36 or higher, coupled with revenue exceeding $1.35 billion, would confirm a strong growth trajectory.
Bear Confirmed If
An EPS below $0.32 and revenue under $1.25 billion would indicate potential struggles in the current market environment.
Implied Move
±N/A
There is no available options market data to gauge investor sentiment ahead of the earnings report.
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
n=30Fade rate: 8 of 20 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 8 of 20 faded and 12 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.8%, with a raw directional average of +2.2% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Elanco beats expectations, history suggests the stock could rise by an average of 12.80%, confirming strong demand and operational efficiency.
In-Line / Cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance and commentary.
Miss
Should Elanco miss expectations, the stock could decline by approximately 3.69%, reflecting investor disappointment and concerns about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026